457. Intensive longitudinal monitoring of symptoms in response to treatment with intranasal esketamine
International Journal of Neuropsychopharmacology September 9, 2026 M Saje, J Bon, A Oblak
Abstract Background Esketamine is a NMDA receptor antagonist that has been approved as treatment for treatment-resistant depression (TRD). Unlike serotoninergic therapies requiring weeks for effect, intranasal esketamine modulates glutamate neurotransmission, often yielding symptom relief within hours and significant response rates within one month [1]. This rapid action is particularly...